[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441248":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":48,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[U-13C]glucose",null,"All participants consented to the study will receive the \\[U-13C\\]glucose infusion and collection of ascites for research.",[13],"Dietary Supplement: [U-13C]Glucose",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIETARY_SUPPLEMENT","[U-13C]Glucose","Patients are intravenously infused with 28g of \\[U-13C\\]glucose over a 5 hour period. Briefly, \\[U-13C\\]glucose will be provided by intravenous line containing 8g of \\[U-13C\\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \\[U-13C\\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Julian J. Lum, PhD","CONTACT","250-519-5700","JLum@bccancer.bc.ca",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Jennifer Rauw, MD","250-519-5500","Jennifer.Rauw@bccancer.bc.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Jennifer Rauw","RECRUITING","Victoria","British Columbia","Canada","CA",{"type":39,"coordinates":40},"Point",[41,42],-123.35155,48.4359,{"lat":42,"lon":41},[45],{"name":27,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49,51,53],{"name":50,"class":6},"University of Texas Southwestern Medical Center",{"name":52,"class":6},"Van Andel Research Institute",{"name":54,"class":6},"University of Victoria","100441248","13c-glucose-tracing-of-tumour-and-t-cells-in-the-ascites-of-ovarian-cancer-patients-100441248",false,"NCT05025878","13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.","Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients","iMETABO","Inclusion Criteria:\n\n* Ovarian cancer\n* Any stage or grade of disease\n* Ascites fluid that requires draining\n* Any treatment regimen\n* Primary or recurrent ascites\n* Understands the concept of the study and give informed consent.\n\nExclusion Criteria:\n\n* Participants must not have diabetes or abnormal hemoglobin A1C levels.\n* The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada.\n* Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.","FEMALE","18 Years",{"count":66,"type":67},10,"ESTIMATED","OBSERVATIONAL","The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \\[U-13C\\]glucose into patients during standard paracentesis.",[71,72],"Ovarian Cancer","Ascites","2024-08-08",{"date":75,"type":76},"2024-08-09","ACTUAL",{"date":78,"type":76},"2021-10-20",{"date":80,"type":67},"2024-08",{"name":5,"class":6},1]